These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32453842)

  • 21. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
    Matsui H; Hegadorn C; Ozelo M; Burnett E; Tuttle A; Labelle A; McCray PB; Naldini L; Brown B; Hough C; Lillicrap D
    Mol Ther; 2011 Apr; 19(4):723-30. PubMed ID: 21285959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hunting down factor VIII in the immunopeptidome.
    Hartholt RB; Peyron I; Voorberg J
    Cell Immunol; 2016 Mar; 301():59-64. PubMed ID: 26610639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse.
    Li YJ; Chen C; Zeng LY; Cao J; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):658-63. PubMed ID: 22739177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
    Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
    Front Immunol; 2020; 11():1293. PubMed ID: 32670285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoter.
    Picanço V; Heinz S; Bott D; Behrmann M; Covas DT; Seifried E; Tonn T
    Cytotherapy; 2007; 9(8):785-94. PubMed ID: 17917890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Storage and regulated secretion of factor VIII in blood outgrowth endothelial cells.
    van den Biggelaar M; Bouwens EA; Kootstra NA; Hebbel RP; Voorberg J; Mertens K
    Haematologica; 2009 May; 94(5):670-8. PubMed ID: 19336741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A.
    Ide LM; Iwakoshi NN; Gangadharan B; Jobe S; Moot R; McCarty D; Doering CB; Spencer HT
    J Gene Med; 2010 Apr; 12(4):333-44. PubMed ID: 20209485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Codon optimization of human factor VIII cDNAs leads to high-level expression.
    Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
    Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A.
    Olgasi C; Talmon M; Merlin S; Cucci A; Richaud-Patin Y; Ranaldo G; Colangelo D; Di Scipio F; Berta GN; Borsotti C; Valeri F; Faraldi F; Prat M; Messina M; Schinco P; Lombardo A; Raya A; Follenzi A
    Stem Cell Reports; 2018 Dec; 11(6):1391-1406. PubMed ID: 30416049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
    Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
    Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells.
    Kaczmarek R; Piñeros AR; Patterson PE; Bertolini TB; Perrin GQ; Sherman A; Born J; Arisa S; Arvin MC; Kamocka MM; Martinez MM; Dunn KW; Quinn SM; Morris JJ; Wilhelm AR; Kaisho T; Munoz-Melero M; Biswas M; Kaplan MH; Linnemann AK; George LA; Camire RM; Herzog RW
    Blood; 2023 Jul; 142(3):290-305. PubMed ID: 37192286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
    Liu CL; Ye P; Yen BC; Miao CH
    Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells.
    Lubich C; Steinitz KN; Hoelbl B; Prenninger T; van Helden PM; Weiller M; Reipert BM
    Front Immunol; 2022; 13():975680. PubMed ID: 36389737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A.
    Johnston JM; Denning G; Doering CB; Spencer HT
    Gene Ther; 2013 Jun; 20(6):607-15. PubMed ID: 22996197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
    Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
    Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
    Shi Q; Kuether EL; Chen Y; Schroeder JA; Fahs SA; Montgomery RR
    Blood; 2014 Jan; 123(3):395-403. PubMed ID: 24269957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deciphering the Ets-1/2-mediated transcriptional regulation of F8 gene identifies a minimal F8 promoter for hemophilia A gene therapy.
    Famà R; Borroni E; Merlin S; Airoldi C; Pignani S; Cucci A; Corà D; Bruscaggin V; Scardellato S; Faletti S; Pelicci G; Pinotti M; Walker GE; Follenzi A
    Haematologica; 2021 Jun; 106(6):1624-1635. PubMed ID: 32467137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.
    Wroblewska A; van Haren SD; Herczenik E; Kaijen P; Ruminska A; Jin SY; Zheng XL; van den Biggelaar M; ten Brinke A; Meijer AB; Voorberg J
    Blood; 2012 May; 119(22):5294-300. PubMed ID: 22498747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.
    Gaitonde P; Purohit VS; Balu-Iyer SV
    Eur J Pharm Sci; 2015 Jan; 66():157-62. PubMed ID: 25459532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.
    Su RJ; Epp A; Latchman Y; Bolgiano D; Pipe SW; Josephson NC
    Mol Ther; 2010 Jan; 18(1):214-22. PubMed ID: 19755963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.